Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

Recent Phase III data presented at the American Society of Clinical Oncology (ASCO) 2013 annual conference by Brose et al led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of well-differentiated radioactive iodine-resistant metastatic thyroid cancer. This is th...

Descripción completa

Detalles Bibliográficos
Autores principales: McFarland, Daniel C, Misiukiewicz, Krzysztof J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105272/
https://www.ncbi.nlm.nih.gov/pubmed/25053887
http://dx.doi.org/10.2147/OTT.S49430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105272/
https://www.ncbi.nlm.nih.gov/pubmed/25053887
http://dx.doi.org/10.2147/OTT.S49430

Ejemplares similares